GlassScriptPhysician profile
Isaac A Loose
NPI 1821075664
$3,842.05
in general payments reported to CMS, 2019-2025
25 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $314 · 2021: $431 · 2022: $779 · 2023: $830 · 2024: $639 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,406 · Entertainment: $144 · Long Term Medical Supply Or Device Loan: $64.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.44 |
| Entertainment | $144.43 |
| Long Term Medical Supply Or Device Loan | $64.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $381.28 | 2019-2022 | |
| Abbvie INC. | $375.91 | 2019-2025 | |
| Genentech USA, INC. | $357.94 | 2021-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $345.88 | 2019-2021 | |
| Astellas Pharma US INC | $271.69 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $233.25 | 2023-2024 | Eylea Hd, Eylea |
| Biotissue Holdings INC. | $197.40 | 2022-2023 | |
| Heidelberg Engineering, INC. | $184.27 | 2021 | |
| Alcon Vision LLC | $166.16 | 2022-2025 | Eysuvis |
| Optos, INC. | $159.85 | 2022-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Mallinckrodt Enterprises LLC | $145.19 | 2019 | |
| Rxsight INC | $143.45 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Apellis Pharmaceuticals, INC. | $142.64 | 2023 | Syfovre |
| Regeneron Pharmaceuticals, INC. | $135.01 | 2022 | |
| Alimera Sciences, INC. | $134.13 | 2019-2023 | Yutiq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $127.94 | 2020 | |
| Bausch & Lomb Americas INC. | $94.63 | 2023-2024 | Miebo, Xiidra, Xipere |
| Allergan, INC. | $84.25 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $64.25 | 2023 | Cirrus Hd-Oct |
| Biogen, INC. | $33.02 | 2022 | |
| Astellas Pharma Global Development | $27.15 | 2025 | Izervay |
| Amgen INC. | $21.83 | 2025 | Tepezza |
| Tearlab Corp | $14.93 | 2023 | Tearlab Osmolarity System |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Loose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.